Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
William Raveis Names Owen Tyler Regional Vice President Of The Carolinas And Georgia
CHARLESTON, S.C., Feb. 13, 2025 /PRNewswire/ -- William Raveis , a premier luxury Real estate brokerage renowned for its exceptional service and market expertise, is pleased to announce the ...
Could Buying Realty Income Stock Today Set You Up for Life?
Realty Income has increased its dividend annually for three decades. The giant net lease REIT has a lofty 5.8% dividend yield ...